| abstract |
REFERS TO AZABENZOTHIOPHENYL COMPOUNDS OF FORMULA (I), WHERE Z1 IS CR1 O N; Z2 IS CR2 O N; Z3 IS CR3 O N; Z4 IS CR4 O N, WHERE ONE OR TWO Z1, Z2, Z3, Z4 ARE N; R1, R2, R3, R4 ARE INDEPENDENTLY H, HALO, CN, CF3, -OF3, (C1-C12) ALKYL, HETEROCYCLYL, AMONG OTHERS; W ES a); R5 AND R6 ARE INDEPENDENTLY H OR ALKYL (C1-C12); X1 IS R11, -OR11, AMONG OTHERS, WHERE OR11 AND R5 COME TOGETHER TO FORM A RING OF 4 TO 7 SUBUNITIES WITH 0 TO 2 HETEROATOMS SELECTED FROM O, S OR N; R11 IS H, (C1-C12) ALKYL, ARYL, AMONG OTHERS; X2 IS CARBOCYCLYL, HETERO CYCLYL, ARYL, OR HETEROARYL. THEY ARE SELECTED: ((R) -2,2-DIMETHYL- [1,3] DIOXOLAN-4-ILMETOXY) -AMIDE OF THE ACID 3- (4-BROMO-2-FLUORO-PHENILAMINO) -TIENO [2,3-c ] PYRIDINE-2-CARBOXYL, 3- (2-FLUORO-4-IODINE-PHENYLAMINE) ACID ETHYL ESTER HAVE [2,3-c] PYRIDINE-2-CARBOXYL, 3-AMINO-7-FLUORO-THENE ACID ETHYL STER [ 3,2-c] PYRIDINE-2-CARBOXYL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF MEK KINASE ACTIVITY, SO THEY INHIBIT ABNORMAL CELL GROWTH, BEING USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS OR INFLAMMATORY DISEASE |